SECURITIES AND EXCHANGE COMMISSION
                                Washington, DC  20549



                                       FORM 8-K




                                    CURRENT REPORT



                        Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934




                                    June 15, 1994



                               Mallinckrodt Group Inc.
                (Exact name of registrant as specified in its charter)










                   New York                1-483            36-1263901
          (State or other jurisdiction  (Commission       (IRS Employer
           of incorporation)             File Number)   Identification No.)

          7733 Forsyth Boulevard, St. Louis, MO             63105-1820
          (Address of principal executive offices)          (Zip Code)

          Registrant's telephone number,               (314) 854-5200
          including area code























          Item 5. Other Events

          A press release was issued June 15, 1994.  The relevant portion
          of the text of that release was as follows:


          Mallinckrodt Medical To Reorganize To Adjust To Health Care
          Market Changes

               Mallinckrodt Group Inc. is disclosing today that its medical
          operating unit will restructure its organization to adapt to
          market changes that are being driven by health care reform and to
          effectively respond to customer needs in an ever-changing and
          more competitive environment.

               President and Chief Executive Officer C.R. Holman said the
          company expects to record a one-time pretax charge of up to $80
          million, or about 65 cents per share, in the fourth quarter to
          cover the restructuring.  The special pretax charge will apply
          only to Mallinckrodt Medical and not to any other part of the
          company, according to Holman.

               "The decision to take this charge is an investment for the
          future of our medical business and has been made after thorough
          evaluation and planning by Mallinckrodt Medical's management
          team.  It is anticipated that the ongoing cost savings from the
          restructuring will be approximately $40 million annually.  We
          expect to achieve most of the savings by 1996," Holman said.

               "Mallinckrodt Group remains committed to long-term growth
          and improved profitability," Holman stated.  "While there can be
          no definitive assurances, we believe that total company sales
          will continue to grow at a rate of 10 to 12 percent annually and
          that earnings growth over the next five years, excluding the
          Mallinckrodt Medical restructuring charge, will be at least 15
          percent.  This is without major acquisitions, which we will
          continue to pursue as viable opportunities are presented.

               "We also remain on track to achieve the profitability goals
          previously communicated for 1998.  Our goal is to reach a 10
          percent return on sales, 15 percent return on invested capital
          and 18 percent return on equity," Holman said.

               Mallinckrodt Medical President and Chief Executive Officer
          Robert G. Moussa said that the unit expects to deliver 1994 sales
          and earnings of about 15 percent over last year, despite some
          moderation in the pace of sales growth and increased price
          discounting this year, without the benefits of restructuring.

               "We are planning for sales to grow at about 12 to 13 percent
          annually over the next five years, benefitting from new products
          such as Albunex and OctreoScan imaging agents, and earnings to
          grow at approximately 14 to 15 percent, resulting from volume
          growth, productivity improvement and cost reductions from the














          restructuring," Moussa said.

               He explained that the structuring program, which the company
          will begin implementing early in FY 95, will include a downsizing
          of the overall workforce of up to 10 percent.  Currently,
          Mallinckrodt Medical employs over 5,000 people, with about two-
          thirds of the employees in the United States.

               A first step in the restructuring will be the reorganization
          of the U.S. sales structure, replacing the current five
          divisional sales groups with a unified sales organization to be
          led by a senior executive.  The U.S. sales organization will be
          divided into geographic districts, each headed by a business
          manager to which a team of account managers and clinical
          specialists will report.

               Mallinckrodt Medical's current U.S. sales force is made up
          of approximately 350 people assigned to one of the five units:
          cardiology, radiology, nuclear medicine, anesthesiology or
          critical care.  Moussa said that the size of the sales
          organization will be determined within several weeks.

               In parallel, programs will be implemented to reduce,
          centralize and standardize certain non-sales related functions
          and management systems to better support the sales structure.  It
          is anticipated that these programs will contribute to lower
          employment.  The restructuring also will address critical
          manufacturing rationalization programs to improve the company's
          cost structure on a worldwide basis.

               "This program eventually will touch all parts of our
          organization," Moussa said.  "The steps we are taking with our
          U.S. sales organization are needed first, but we also will look
          to other parts of the company and our international operations in
          the future.  Programs will be developed and implemented as
          quickly as possible, with most of the anticipated annual savings
          to be achieved during fiscal 1996.

               "Throughout the restructuring, we will continue to provide
          our customers with the same high quality products and services
          they expect and deserve from us.  In the end, we expect to have
          an organization that will allow us to remain flexible to address
          future change.  We also are intent on taking the steps needed to
          reduce costs, remain competitive and sustain our strong market
          presence," Moussa said.

               Mallinckrodt Group Inc. is a Fortune 250 company, which
          moved its corporate headquarters to St. Louis, Mo., from
          Northbrook, Ill., and changed its name from IMCERA in March.  Net
          sales are forecast to be over $1.9 billion for FY 94, which ends
          June 30.  Through its three technology-based businesses -
          Mallinckrodt Chemical and Mallinckrodt Medical (both
          headquartered in St. Louis) and Mallinckrodt Veterinary
          (headquartered in Mundelein, Ill.) - the company provides human














          and animal health care products and specialty chemicals. 
          Mallinckrodt Group and its subsidiaries have approximately 10,000
          employees worldwide.

                                         ###

               Pursuant to the requirements of the Securities Exchange Act
          of 1934, the registrant has duly caused this report to be signed
          on its behalf by the undersigned thereunto duly authorized.


          Mallinckrodt Group Inc.

          ROGER A. KELLER


          ________________________________
          Roger A. Keller
          Vice President, Secretary and General Counsel


          Date:  June 27, 1994